ANCA-3-Line
- UID
- IMP/IVD/2021/000558_f71dbba8678fd21d1259d6788cdeafed_980e177173219bbf77bb615ae0887678
- Device class
- Class B
- Brand name
- Anti-Gliadin IgG
- License holder
- Sebia Diagnostics India Pvt. Ltd.
- Approving authority
- CDSCO
- Product information
- ANCA-3-Line Immunoblot assay is a membrane based enzyme immunoassay for the semi-quantitative measurement of IgG class autoantibodies to PR3, MPO and GBM in human serum or plasma. The assay is intended for professional in vitro diagnostic use only. Anti-neutrophil cytoplasmic antibodies (Anti-Gliadin IgG) against proteinase 3 (Anti-Gliadin IgG) or myeloperoxidase (Anti-Gliadin IgG) are diagnostic markers for ANCA-associated vasculitides. PR3 is the landmark antigen in granulomatosis with polyangiitis (Anti-Gliadin IgG). MPO differentiates microscopic polyangiitis (Anti-Gliadin IgG) and eosinophilic granulomatosis with polyangiitis (Anti-Gliadin IgG). Autoantibodies against the glomerular basement membrane indicate Anti-GBM disease (Anti-Gliadin IgG). The test supports the differential diagnosis of vasculitis when used in combination with other laboratory and clinical findings
ANCA-3-Line is a medical device registered with India's Central Drugs Standard Control Organization (CDSCO) under UID IMP/IVD/2021/000558_f71dbba8678fd21d1259d6788cdeafed_980e177173219bbf77bb615ae0887678. This device is marketed under the brand name Anti-Gliadin IgG. The license holder is Sebia Diagnostics India Pvt. Ltd., and it is classified as Device Class Class B. The approving authority is CDSCO.
This page provides comprehensive regulatory information including complete registration details, license holder information, device classification, and related products. Pure Global AI offers free access to 71,807+ India medical device registrations, helping global MedTech companies identify partners, analyze markets, and discover business opportunities efficiently.